Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.

ABSTRACT:

Aims/introduction

Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available.

Methods

This was an investigator-initiated multicenter prospective intervention study in which ipragliflozin (50 mg) was administered once daily, and glycemic control, estimated glomerular filtration rate (eGFR) and adverse events were evaluated until 104 weeks after starting research.

Results

There were 407 patients analyzed. In the eGFR ≥90 group and eGFR ≥60 to <90 group, eGFR had significantly decreased compared with baseline at all time points from 4 to 104 weeks. There were significant increases in the eGFR ≥45 to <60 groups compared with baseline at 36 weeks (2.3 ± 1.0) and 52 weeks (2.6 ± 1.2). Comparison between th

SUBMITTER: Matsuba I 

PROVIDER: S-EPMC7477528 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature